Thursday, December 25, 2025 12/25/2025

IND-enabling studies for Aspartylglucosaminuria (AGU) to support the initiation of an AAV9/AGA gene transfer clinical trial

Award Number: U01NS129339
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2023
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

IND-enabling studies for Aspartylglucosaminuria (AGU) to support the initiation of an AAV9/AGA gene transfer clinical trial - A faulty AGA gene coding for the dysfunctional enzyme results in a severe and progressive genetic neurological disorder, Aspartylglucosaminuria (AGU, OMIM # 208400). The functional enzyme is required for the breakdown of glycoproteins in the cellular lysosomes. Absence of enzymatic activity results in impaired lysosomal function and accumulation of aspartylglucosamine (GlcNAc-Asn) in the lysosomes of various tissues and body fluids. The key consequence of the substrate accumulation is lysosomal hypertrophy that manifests as intellectual disability, and other associated symptoms including skeletal and joint abnormalities. Patients have slowed/regressive psychomotor development throughout childhood, deteriorating around the third decade of life to become severely impaired mentally and physically, highly dependent on supportive care thereafter. The median lifespan of AGU patients is approximately 40-50 years. Through efforts primarily funded through a parent-organized non-profit foundation, the Rare Trait Hope Fund, Dr. Gray’s lab has generated preclinical data supporting the initiation of a Phase I/II gene therapy trial to treat AGU. A Type B preIND meeting was held with the FDA regarding this in January 2018, which has charted a clear path forward for human translation. This approach would use an AAV9/AGA vector injected intrathecally, following a precedent set by Dr. Gray’s previous efforts to initiate similar Phase I trials for Giant Axonal Neuropathy at the NIH Clinical Center in 2015 and for CLN7 Batten disease at Children’s Medical Center Dallas in 2021. The wealth of available disease-specific biomarkers for AGU (including localized imaging of the AGA enzyme substrate in discrete brain regions) along with a potentially large treatment window, make AGU an ideal disease to rapidly and fully assess the complete efficacy and/or shortcomings of intrathecal AAV9 as a “platform” approach to treat many other neurological diseases. We propose to conduct the necessary IND-enabling studies to initiate a Phase I/II clinical trial for AGU.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	12/19/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $744,158 )
2025	2025	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	3	9/4/2025	NON-COMPETING CONTINUATION	$744,158
2025	2024	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	5/9/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $744,158

Issue Date FY: 2024 ( Subtotal = $773,534 )
2024	2024	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	8/14/2024	NON-COMPETING CONTINUATION	$773,534
														Subtotal = $773,534

Issue Date FY: 2023 ( Subtotal = $631,697 )
2023	2023	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	8/24/2023	NEW	$631,697
														Subtotal = $631,697

Grand Total All Awards = $2,149,389

Top

All Categories

About

Search

Reports

Data Submission

Award Information

IND-enabling studies for Aspartylglucosaminuria (AGU) to support the initiation of an AAV9/AGA gene transfer clinical trial

Award Number: U01NS129339

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2023

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer